Marshall Wace
MRSN

Marshall Wace’s Mersana Therapeutics MRSN Stock Holding History

Marshall Wace’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,079
Closed -$68.1K – 3213
2025
Q2 		$68.1K Buy
+9,079
New +$79.8K ﹤0.01% 2575
2025
Q1 		– Sell
-624
Closed -$22.3K – 2915
2024
Q4 		$22.3K Buy
+624
New +$32.3K ﹤0.01% 2508
2024
Q3 		– Sell
-7,041
Closed -$354K – 2801
2024
Q2 		$354K Buy
7,041
+5,504
+358% +$398K ﹤0.01% 2092
2024
Q1 		$172K Sell
1,537
-4,775
-76% -$475K ﹤0.01% 2256
2023
Q4 		$366K Hold
6,312
– – ﹤0.01% 1829
2023
Q3 		$200K Sell
6,312
-102,140
-94% -$4.85M ﹤0.01% 1975
2023
Q2 		$8.92M Buy
108,452
+8,584
+9% +$1.26M 0.02% 787
2023
Q1 		$10.3M Sell
99,868
-1,091
-1% -$153K 0.02% 706
2022
Q4 		$14.8M Buy
100,959
+79,820
+378% +$13.5M 0.03% 598
2022
Q3 		$3.57M Buy
+21,139
New +$3.44M 0.01% 1622
2022
Q2 		– Sell
-1,307
Closed -$130K – 3694
2022
Q1 		$130K Buy
+1,307
New +$153K ﹤0.01% 3168
2021
Q4 		– Sell
-15,389
Closed -$3.63M – 4147
2021
Q3 		$3.63M Buy
15,389
+14,595
+1,838% +$4.26M 0.02% 1151
2021
Q2 		$269K Sell
794
-5,290
-87% -$2M ﹤0.01% 2361
2021
Q1 		$2.46M Buy
6,084
+2,120
+53% +$1.03M 0.01% 1213
2020
Q4 		$2.64M Buy
+3,964
New +$2.2M 0.01% 832
2019
Q4 		– Sell
-4,862
Closed -$192K – 1939
2019
Q3 		$192K Sell
4,862
-2,033
-29% -$148K ﹤0.01% 1291
2019
Q2 		$698K Buy
6,895
+5,825
+544% +$686K 0.01% 1014
2019
Q1 		$141K Buy
+1,070
New +$135K ﹤0.01% 1388

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's MRSN Position: Q3 2025 in Review

Marshall Wace sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 9,079 shares — an estimated $68.1K sold.

Marshall Wace first reported a position in MRSN in Q1 2019 and held it in 18 quarters. The position peaked at $14.8M in Q4 2022. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Marshall Wace reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 9,079 Mersana Therapeutics shares in Q3 2025, an estimated $68.1K.
  • Marshall Wace first reported a position in Mersana Therapeutics in Q1 2019 and held it in 18 quarters.
  • Marshall Wace's Mersana Therapeutics position peaked at $14.8M in Q4 2022.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.